Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy
Authors:
- 21 April 2023
- journal article
- research article
- Published by Springer Nature in Science China Life Sciences
- Vol. 66 (10) , 2310-2328
Abstract
Although immune checkpoint inhibition has been shown to effectively activate antitumor immunity in various tumor types, only a small subset of patients can benefit from PD-1/PD-L1 blockade. CD47 expressed on tumor cells protects them from phagocytosis through interaction with SIRPα on macrophages, while PD-L1 dampens T cell-mediated tumor killing. Therefore, dual targeting PD-L1 and CD47 may improve the efficacy of cancer immunotherapy. A chimeric peptide Pal-DMPOP was designed by conjugating the double mutation of CD47/SIRPα blocking peptide (DMP) with the truncation of PD-1/PD-L1 blocking peptide OPBP-1(8–12) and was modified by a palmitic acid tail. Pal-DMPOP can significantly enhance macrophage-mediated phagocytosis of tumor cells and activate primary T cells to secret IFN-γ in vitro. Due to its superior hydrolysis-resistant activity as well as tumor tissue and lymph node targeting properties, Pal-DMPOP elicited stronger anti-tumor potency than Pal-DMP or OPBP-1(8–12) in immune-competent MC38 tumor-bearing mice. The in vivo anti-tumor activity was further validated in the colorectal CT26 tumor model. Furthermore, Pal-DMPOP mobilized macrophage and T-cell anti-tumor responses with minimal toxicity. Overall, the first bispecific CD47/SIRPα and PD-1/PD-L1 dual-blockade chimeric peptide was designed and exhibited synergistic anti-tumor efficacy via CD8+ T cell activation and macrophage-mediated immune response. The strategy could pave the way for designing effective therapeutic agents for cancer immunotherapy.Keywords
This publication has 66 references indexed in Scilit:
- Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer ImmunotherapyAngewandte Chemie International Edition, 2015
- Peptide therapeutics: current status and future directionsDrug Discovery Today, 2015
- Peptide-based cancer therapy: Opportunity and challengeCancer Letters, 2014
- The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic TargetAnnual Review of Immunology, 2014
- Structure-based programming of lymph-node targeting in molecular vaccinesNature, 2014
- Fatty acid binding to serum albumin: Molecular simulation approachesBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Chemokine nitration prevents intratumoral infiltration of antigen-specific T cellsJournal of Experimental Medicine, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Imaging of αvβ3 Expression by a Bifunctional Chimeric RGD Peptide not Cross-Reacting with αvβ5Clinical Cancer Research, 2009
- Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47Molecular Cell, 2008